Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effect on the body of Tabalumab
(LY2127399) in combination with bortezomib and dexamethasone in Japanese participants with
relapsed or refractory multiple myeloma (MM).